<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429714</url>
  </required_header>
  <id_info>
    <org_study_id>10-2-026</org_study_id>
    <secondary_id>80-82310-97-11017</secondary_id>
    <nct_id>NCT01429714</nct_id>
  </id_info>
  <brief_title>The Ideal Deep Venous Thrombosis (DVT) Study</brief_title>
  <acronym>IDEAL</acronym>
  <official_title>Individually Tailored Elastic Compression Therapy After Deep Venous Thrombosis in Relation to the Incidence of Post Thrombotic Syndrome, a Randomized Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the Netherlands, 25.000 patients each year are diagnosed with Deep Venous Thrombosis
      (DVT). Elastic compression stocking (ECS) therapy reduces the incidence of post thrombotic
      syndrome (PTS) following DVT from 50% without ECS to 20-30% after ECS therapy for two years.
      It is however unclear whether all patients benefit to the same extent from this therapy or
      what the optimal duration of ECS therapy for individual patients should be. ECS therapy is
      not only costly, inconvenient and demanding but sometimes also even debilitating. Substantial
      costs could be saved by tailoring therapy to individual needs and as a result the quality of
      life for individual patients can be expected to improve.

      This study aims to assess the costs and effects of tailoring the duration of ECS therapy
      after DVT to individual patients needs.

      ECS therapy with a standard duration of 24 months will be compared with tailored ECS therapy,
      following an initial therapeutic period of 6 months, in patients with acute proximal DVT. The
      primary outcome is the percentage of patients with PTS at two year follow-up.

      This is a multi-center, randomized, allocation concealed, single-blinded clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 22, 2011</start_date>
  <completion_date type="Actual">July 1, 2017</completion_date>
  <primary_completion_date type="Actual">July 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The occurrence of PTS at 24 months after the event of acute DVT</measure>
    <time_frame>At 24 months after the event of the acute DVT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life (HRQOL)</measure>
    <time_frame>Baseline, 3, 6, 12 and 24 months</time_frame>
    <description>HRQOL, will be measured by questionnaires SF-36, EuroQol-5D, Veines-Qol Dutch translated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent venous thrombosis</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality due to venous thrombosis</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>3, 6, 12, 24 months</time_frame>
    <description>Costs will include direct costs (e.g. medical therapy) and indirect costs (e.g. travel) and will be measured by case record forms, hospital data and 5 retrospective cost-questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Preferences</measure>
    <time_frame>baseline, 24 months</time_frame>
    <description>Patient preferences will be elicited by conducting a discrete choice experiment (DCE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">865</enrollment>
  <condition>Postthrombotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Intervention: individually tailored ECS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individually tailored duration of elastic compression therapy, based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: ECS 24 months</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Elastic compression therapy with a standard duration of 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Individually tailored duration of elastic compression therapy</intervention_name>
    <description>Individually tailored duration of elastic compression therapy,based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months</description>
    <arm_group_label>Intervention: individually tailored ECS</arm_group_label>
    <other_name>Custom made flat knitted, knee length, class III stockings (Mediven ®550, ankle pressure 40 mmHg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Elastic compression therapy with a standard duration of 24 months</intervention_name>
    <description>Elastic compression therapy with a standard duration of 24 months</description>
    <arm_group_label>Control: ECS 24 months</arm_group_label>
    <other_name>Custom made flat knitted, knee length, class III stockings (Mediven ®550, ankle pressure 40 mmHg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Legal age (18 yrs)

          -  Informed consent

          -  Acute objectively documented DVT of the leg

          -  Adequate anticoagulation

        Exclusion Criteria:

          -  Previous DVT in the affected leg

          -  Recurrent DVT in the first 6 months following inclusion

          -  Preexistent venous insufficiency (skin signs C4-C6 on CEAP score or requiring ECS
             therapy)

          -  Contraindication for elastic compression therapy (arterial insufficiency)

          -  Active thrombolysis

          -  Life expectancy &lt; 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arina J ten Cate-Hoek, MD, PhD, MpH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padua</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Treviso Aziende</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flevohospital</name>
      <address>
        <city>Almere</city>
        <zip>1315 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slotervaart hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medical Centre</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Medical Centre</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westfriesgasthuis</name>
      <address>
        <city>Hoorn</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Nijmegen Radboud</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurentius ziekenhuis</name>
      <address>
        <city>Roermond</city>
        <zip>6043 CV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Ten Cate-Hoek AJ, Bouman AC, Joore MA, Prins M, Ten Cate H; IDEAL DVT trial investigators. The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial. BMJ Open. 2014 Sep 4;4(9):e005265. doi: 10.1136/bmjopen-2014-005265.</citation>
    <PMID>25190617</PMID>
  </reference>
  <reference>
    <citation>Ten Cate-Hoek AJ, Amin EE, Bouman AC, Meijer K, Tick LW, Middeldorp S, Mostard GJM, Ten Wolde M, van den Heiligenberg SM, van Wissen S, van de Poel MH, Villalta S, Serné EH, Otten HM, Klappe EH, Bistervels IM, Lauw MN, Piersma-Wichers M, Prandoni P, Joore MA, Prins MH, Ten Cate H; IDEAL DVT investigators. Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. Lancet Haematol. 2018 Jan;5(1):e25-e33. doi: 10.1016/S2352-3026(17)30227-2. Epub 2017 Dec 5.</citation>
    <PMID>29217387</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Elastic Compression Stockings</keyword>
  <keyword>Deep Venous Thrombosis</keyword>
  <keyword>Post Thrombotic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Postthrombotic Syndrome</mesh_term>
    <mesh_term>Postphlebitic Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

